From GlobeNewswire: 2025-06-18 08:20:00

The global ELISpot and Fluorospot Assay Market was valued at USD 290.92 million in 2023, projected to reach USD 528.30 million by 2032 with a CAGR of 6.85%. The U.S. market alone was valued at USD 79.68 million in 2023, estimated to climb to USD 138.33 million by 2032 with a CAGR of 6.32%. Increasing demand for immune response assays in infectious disease diagnostics, cancer immunotherapy, and autoimmune disease research is driving market growth. ELISpot and Fluorospot assays are widely used in vaccine development, autoimmune disease studies, and cancer immunotherapy, supported by the rising demand for high-sensitivity diagnostics. Key players in the market include Becton, Dickinson, and Company, U-CyTech biosciences, Cellular Technologies Limited, Mabtech AB, and more.

The assay kits segment captured the highest market share of 48.56% in 2023, with analyzers expected to grow at the highest rate due to demand for automated and high-throughput analyzers in research settings. Diagnostic applications held 65.41% of the market share in 2023, while research applications are expected to witness rapid growth. Hospitals and clinical laboratories accounted for the largest share of 47.25% in 2023, with biopharmaceutical and research institutes expected to grow at the fastest rate.

North America dominated the global market in 2023, with the U.S. holding approximately 40% of the market share. The Asia-Pacific market is expected to have the highest growth rate until 2032. Recent developments include BD announcing the separation of its Biosciences and Diagnostic Solutions business, U-CyTech Biosciences being recognized as a leading company, and Cellular Technology Limited being identified as a major player in the market.

Statistical insights and trends indicate the U.S. accounted for 40% of the global market share in 2023, with the total number of assay kits and analyzers expected to increase by 70% between 2024 and 2032. Spending on immunology-based diagnostics increased by 9.5% in 2023, and the use of ELISpot and Fluorospot assays in immuno-oncology research is expected to grow by 85% by 2032.

SNS Insider is a leading market research and consulting agency providing clients with current, accurate market data, consumer insights, and opinions to make informed decisions. Their aim is to give clients the knowledge they need to navigate changing circumstances through a variety of research techniques.



Read more at GlobeNewswire: ELISpot and Fluorospot Assay Market Set to Reach USD 528.30